Mechanisms of Drug Interactions — MCQs

10 questions

Which of the following statements is true regarding competitive reversible antagonism?

The dose of Digoxin should be reduced when given along with which medication?

A factor that is likely to increase the duration of action of a drug that is partially metabolized by CYP3A4 in the liver is:

All are true for cytochrome P450 enzymes EXCEPT:

The anticoagulant activity of warfarin can be reduced by all of the following except.

Which of the following describes the first-pass metabolism?

With which of the following receptors does theophylline have an antagonistic interaction?

What is the primary purpose of xenobiotic metabolism?

Which of the following drugs is metabolized by CYP2D6?

Q10

Which antiretroviral drug should be avoided in a known sputum-positive pulmonary tuberculosis patient who is currently on INH, rifampicin, pyrazinamide, and ethambutol, and has a CD4 count of 100 cells/dL and a viral load of more than 50,000 copies/mL, given that the patient is HIV-positive?

Mechanisms of Drug Interactions Indian Medical PG Practice Questions and MCQs

Question 1: Which of the following statements is true regarding competitive reversible antagonism?

A. ED50 remains unchanged in competitive reversible antagonism.
B. Efficacy and Vmax remain unchanged. (Correct Answer)
C. Potency remains unchanged in the presence of a competitive antagonist.
D. Affinity (Kd) remains unchanged in competitive reversible antagonism.

Explanation: ***Efficacy and Vmax remain unchanged.*** - In competitive reversible antagonism, the antagonist binds to the same receptor site as the agonist but can be overcome by increasing the agonist concentration [2]. This means the **maximum effect (efficacy or Vmax)** of the agonist can still be achieved, although a higher dose is needed [2]. - The antagonist does not alter the intrinsic ability of the agonist to produce a full response, only its **apparent affinity** for the receptor. - This is the hallmark of competitive reversible antagonism: **rightward shift of the dose-response curve with no change in maximum response** [2]. *Potency remains unchanged in the presence of a competitive antagonist.* - **Potency** is a measure of the amount of drug needed to produce a given effect (often defined by EC50 or ED50) [3]. - A competitive antagonist requires a **higher concentration of agonist** to achieve the same effect, thus **decreasing the apparent potency** of the agonist [4]. - The dose-response curve shifts to the right (parallel shift) [4]. *ED50 remains unchanged in competitive reversible antagonism.* - **ED50 (effective dose 50)** is the dose that produces 50% of the maximum effect. - Because competitive antagonists shift the dose-response curve to the right, a **higher ED50** is required to achieve 50% of the maximum effect in the presence of an antagonist [4]. *Affinity (Kd) remains unchanged in competitive reversible antagonism.* - The **dissociation constant (Kd)** represents the affinity of a drug for its receptor [1]. - In competitive reversible antagonism, the antagonist increases the **apparent Kd** of the agonist (reduces apparent affinity), requiring more agonist to achieve receptor occupancy. - The **intrinsic Kd** of the agonist doesn't change, but its apparent affinity is reduced due to competition with the antagonist.

Question 2: The dose of Digoxin should be reduced when given along with which medication?

A. Quinidine (Correct Answer)
B. Rifampicin
C. Indomethacin
D. Antacids

Explanation: ***Quinidine*** - **Quinidine** is known to increase **digoxin plasma concentrations** by inhibiting its renal and non-renal clearance and by displacing it from tissue-binding sites. - This interaction can significantly elevate digoxin levels, necessitating a **dose reduction** [1] to avoid **digoxin toxicity**. *Rifampicin* - **Rifampicin** induces hepatic enzymes, leading to an **increased metabolism** of many drugs, including digoxin. - This interaction would typically *decrease* digoxin levels, potentially requiring an **increase** in digoxin dose, not a reduction. *Indomethacin* - **Indomethacin** and other **NSAIDs** can impair renal function, which *may* indirectly affect digoxin clearance. - However, it does not have a direct, significant interaction with digoxin that would commonly require a primary dose reduction of digoxin for healthy kidneys. *Antacids* - **Antacids** can *reduce the absorption* of some drugs by altering gastric pH or adsorbing the drug. - While they can slightly decrease digoxin absorption if taken concurrently, this effect is usually not significant enough to necessitate a **digoxin dose reduction** in most clinical settings.

Question 3: A factor that is likely to increase the duration of action of a drug that is partially metabolized by CYP3A4 in the liver is:

A. Chronic administration of phenobarbital with the drug
B. Displacement from tissue binding sites by another drug
C. Chronic administration of rifampicin
D. Chronic administration of cimetidine with the drug (Correct Answer)

Explanation: ***Chronic administration of cimetidine with the drug*** - **Cimetidine** is a potent inhibitor of various **cytochrome P450 (CYP450) enzymes**, including **CYP3A4**. - By inhibiting the metabolism of a drug predominantly metabolized by **CYP3A4**, cimetidine will increase its plasma concentration and extend its **duration of action**. *Chronic administration of phenobarbital with the drug* - **Phenobarbital** is a strong **inducer of CYP450 enzymes**, including **CYP3A4**. - Induction would accelerate the metabolism of the drug, thus **decreasing its duration of action**, not increasing it. *Displacement from tissue binding sites by another drug* - Displacement from tissue binding sites would primarily increase the **free fraction of the drug in the plasma**, leading to a more rapid distribution to eliminating organs and potentially **shorter duration of action** if elimination is extraction-limited. - This mechanism does not directly impact the **metabolic rate** unless clearance is significantly altered through increased availability for metabolism. *Chronic administration of rifampicin* - **Rifampicin** is a potent **inducer of CYP3A4** and other CYP enzymes. - Its administration would lead to **increased metabolism** of the co-administered drug, thereby **reducing its duration of action**.

Question 4: All are true for cytochrome P450 enzymes EXCEPT:

A. Synthesize amino acids (Correct Answer)
B. Involved in drug metabolism
C. Present mainly in the liver
D. Part of Phase I metabolism

Explanation: ***Synthesize amino acids*** - Cytochrome P450 enzymes are primarily involved in the **metabolism of xenobiotics** and endogenous compounds, not in the synthesis of amino acids. - **Amino acid synthesis** occurs through different metabolic pathways involving various enzymes distinct from the cytochrome P450 system. *Involved in drug metabolism* - Cytochrome P450 enzymes are a major group of enzymes crucial for the **biotransformation of numerous drugs** and other foreign compounds. - They typically catalyze **oxidation reactions**, preparing drugs for excretion. *Present mainly in the liver* - While present in many tissues, the **highest concentration and diversity** of cytochrome P450 enzymes are found in the **liver**, which is the primary site of drug metabolism. - They are also found in the gastrointestinal tract, kidney, lung, and brain, but to a lesser extent. *Part of Phase I metabolism* - Cytochrome P450 enzymes are the **principal enzymes responsible for Phase I reactions** in drug metabolism. - **Phase I metabolism** generally involves reduction, oxidation, or hydrolysis reactions to introduce polar groups to the drug molecule.

Question 5: The anticoagulant activity of warfarin can be reduced by all of the following except.

A. Aspirin (Correct Answer)
B. Rifampin
C. Vitamin K
D. Carbamazepine

Explanation: ***Aspirin*** - **Aspirin** does NOT reduce warfarin's anticoagulant activity; instead, it increases the risk of bleeding through a synergistic effect. - Aspirin inhibits platelet aggregation via **cyclooxygenase-1 (COX-1)** inhibition, preventing thromboxane A2 formation, which is a different mechanism from warfarin's inhibition of vitamin K-dependent clotting factors. - When combined with warfarin, aspirin **potentiates** the overall antithrombotic effect and increases bleeding risk. *Carbamazepine* - **Carbamazepine** is a potent inducer of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - By increasing warfarin metabolism, it **reduces** warfarin's plasma concentrations and decreases its anticoagulant effect. - Patients on this combination may require higher warfarin doses to maintain therapeutic INR. *Rifampin* - **Rifampin** is one of the most potent inducers of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - It significantly increases warfarin metabolism, leading to **reduced** plasma concentrations and diminished anticoagulant effect. - This interaction often necessitates substantial increases in warfarin dosage. *Vitamin K* - **Vitamin K** is the direct antagonist of warfarin's mechanism of action. - Warfarin inhibits vitamin K epoxide reductase, preventing the regeneration of active vitamin K needed for synthesis of clotting factors II, VII, IX, and X. - Administration of vitamin K **reverses** warfarin's anticoagulant effect by bypassing the inhibited enzyme and restoring clotting factor production.

Question 6: Which of the following describes the first-pass metabolism?

A. Drug given orally is metabolized by the liver before entering the circulation. (Correct Answer)
B. Drug given intravenously bypasses the liver initially.
C. Gastric acids primarily affect the stability of drugs.
D. Absorption of a drug occurs in the intestines.

Explanation: ***Drug given orally is metabolized by the liver before entering the circulation.*** - **First-pass metabolism**, also known as **presystemic metabolism**, refers to the phenomenon where a drug is extensively metabolized in the **gastrointestinal tract** and **liver** before it reaches systemic circulation. - This process significantly reduces the **bioavailability** of orally administered drugs, as a substantial portion of the drug is inactivated or converted to metabolites before it can exert its therapeutic effect. *Drug given intravenously bypasses the liver initially.* - While intravenous (IV) administration does bypass **first-pass metabolism** in the liver and gastrointestinal tract, this statement describes what happens with IV drugs, not the first-pass metabolism itself. - IV drugs enter the **systemic circulation** directly, achieving 100% bioavailability, unlike orally administered drugs affected by first-pass metabolism. *Gastric acids primarily affect the stability of drugs.* - **Gastric acids** primarily affect the **chemical stability** and degradation of certain drugs, but this is a separate phenomenon from first-pass metabolism. - While acid degradation can reduce drug absorption, first-pass effect specifically refers to metabolic transformation in the gut wall and liver. *Absorption of a drug occurs in the intestines.* - The **small intestine** is indeed the primary site for drug absorption due to its large surface area and rich blood supply. - However, this statement describes **drug absorption** in general, not specifically the process of first-pass metabolism, which occurs *after* absorption and involves metabolism before systemic circulation.

Question 7: With which of the following receptors does theophylline have an antagonistic interaction?

A. Histamine receptors
B. Adenosine receptors (Correct Answer)
C. Imidazoline receptors
D. Bradykinin receptors

Explanation: ***Adenosine receptors*** - **Theophylline** acts as a **non-selective competitive antagonist** at **adenosine receptors** (A1, A2A, and A2B). - This antagonism contributes to its **bronchodilator effects** by blocking adenosine-induced bronchoconstriction and to its **stimulant effects** by enhancing neurotransmitter release. *Histamine receptors* - Theophylline does not primarily interact with **histamine receptors**. Its effects are mediated through different mechanisms. - While histamine plays a role in allergic reactions and airway smooth muscle contraction, theophylline's direct action is not on these receptors. *Imidazoline receptors* - Theophylline does not have a significant antagonistic interaction with **imidazoline receptors**. - These receptors are primarily involved in blood pressure regulation and sympathetic outflow, and are not a key target for theophylline's therapeutic effects. *Bradykinin receptors* - Theophylline does not directly antagonize **bradykinin receptors**. - Bradykinin is a potent vasodilator and inflammatory mediator, but its receptors are not the primary site of action for theophylline.

Question 8: What is the primary purpose of xenobiotic metabolism?

A. Increase water solubility (Correct Answer)
B. Increase lipid solubility
C. Make them nonpolar
D. None of the above

Explanation: ***Increase water solubility*** - The primary goal of xenobiotic metabolism is to make these foreign compounds more **hydrophilic** (water-soluble). - This increased water solubility facilitates their **excretion** from the body via urine or bile. *Increase lipid solubility* - Increasing **lipid solubility** would make xenobiotics more likely to accumulate in **adipose tissue** and pass through cell membranes, hindering their excretion. - This is the opposite of the desired outcome for xenobiotic elimination. *Make them nonpolar* - Making xenobiotics **nonpolar** would be equivalent to increasing their lipid solubility, as nonpolar molecules tend to be lipid-soluble. - This would impede excretion and potentially lead to **bioaccumulation**, which is harmful. *None of the options* - This option is incorrect because xenobiotic metabolism specifically aims to increase **water solubility** for elimination.

Question 9: Which of the following drugs is metabolized by CYP2D6?

A. Propranolol (Correct Answer)
B. Warfarin
C. Statins
D. Amiodarone

Explanation: ***Correct Answer: Propranolol*** - **Propranolol** is a non-selective beta-blocker that undergoes extensive **first-pass metabolism**, primarily via the **CYP2D6** and CYP1A2 enzymes. - Genetic variations in **CYP2D6** can significantly affect propranolol's metabolism, leading to altered drug levels and therapeutic responses. *Incorrect: Warfarin* - **Warfarin** is predominantly metabolized by **CYP2C9**, with minor contributions from other CYP enzymes. - Genetic polymorphisms in **CYP2C9** are a major factor in determining individual warfarin dose requirements. *Incorrect: Statins* - Most **statins** (e.g., simvastatin, lovastatin, atorvastatin) are primarily metabolized by **CYP3A4**. - **Fluvastatin** is an exception, being mainly metabolized by CYP2C9, while **rosuvastatin** is largely unmetabolized. *Incorrect: Amiodarone* - **Amiodarone** is primarily metabolized by **CYP3A4** and to a lesser extent by CYP2C8. - Due to its **long half-life** and extensive metabolism, amiodarone has numerous drug interactions, often involving CYP3A4 inhibition.

Question 10: Which antiretroviral drug should be avoided in a known sputum-positive pulmonary tuberculosis patient who is currently on INH, rifampicin, pyrazinamide, and ethambutol, and has a CD4 count of 100 cells/dL and a viral load of more than 50,000 copies/mL, given that the patient is HIV-positive?

A. Indinavir
B. Ritonavir (Correct Answer)
C. Lamivudine
D. Efavirenz

Explanation: ***Ritonavir (Correct Answer)*** - **Ritonavir** is the most critical drug to avoid due to severe drug-drug interactions with **rifampicin** - **Rifampicin** is a potent CYP3A4 inducer that dramatically reduces ritonavir plasma concentrations by 75-90%, rendering it completely ineffective - Ritonavir is commonly used as a pharmacokinetic booster for other protease inhibitors, making this interaction particularly significant - **Contraindicated** with rifampicin-based TB regimens *Indinavir* - Also a protease inhibitor metabolized via CYP3A4 - Should also be **avoided with rifampicin** as levels are reduced by approximately 90% - However, indinavir is rarely used in modern ART regimens due to high pill burden, need for dietary restrictions, and significant side effects (nephrolithiasis) - Less commonly used than ritonavir, making ritonavir the better answer *Lamivudine* - Nucleoside reverse transcriptase inhibitor (NRTI) with **renal elimination** - Not metabolized by CYP450 enzymes - **No significant interactions** with rifampicin or other anti-TB drugs - Safe and commonly used in TB/HIV co-infection *Efavirenz* - Non-nucleoside reverse transcriptase inhibitor (NNRTI) that **can be safely co-administered** with rifampicin - Standard dose (600 mg daily) is generally adequate, though some guidelines recommend considering 800 mg in patients >60 kg - **Preferred NNRTI** for TB/HIV co-infection according to WHO guidelines - Well-studied and effective combination with rifampicin-based TB therapy

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free